Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China.
Int J Mol Med. 2024 Dec;54(6). doi: 10.3892/ijmm.2024.5429. Epub 2024 Sep 20.
Liver fibrosis is a pathophysiologic manifestation of chronic liver disease and a precursor to cirrhosis and hepatocellular carcinoma. Glycolysis provides intermediate metabolites as well as energy support for cell proliferation and phenotypic transformation in liver fibers. 6‑Phosphofructo‑2‑kinase/fructose‑2,6‑bisphosphatase 3 (PFKFB3) is a key activator of glycolysis and plays an important role in the process of glycolysis. The role of PFKFB3‑mediated glycolysis in myocardial fibrosis, renal fibrosis and pulmonary fibrosis has been demonstrated, and the role of PFKFB3 in the activation of hepatic stellate cells by aerobic glycolysis has been proven by relevant experiments. The present study reviews the research progress on the role and mechanism of action of PFKFB3‑mediated glycolysis in the progression of hepatic fibrosis to discuss the role of PFKFB3‑mediated glycolysis in hepatic fibrosis and to provide new ideas for research on PFKFB3 as a target for the treatment of hepatic fibrosis.
肝纤维化是慢性肝病的病理生理表现,是肝硬化和肝细胞癌的前体。糖酵解为肝纤维细胞的增殖和表型转化提供中间代谢产物和能量支持。6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶 3(PFKFB3)是糖酵解的关键激活剂,在糖酵解过程中发挥重要作用。PFKFB3 介导的糖酵解在心肌纤维化、肾纤维化和肺纤维化中的作用已得到证实,相关实验证明了 PFKFB3 在有氧糖酵解激活肝星状细胞中的作用。本研究综述了 PFKFB3 介导的糖酵解在肝纤维化进展中的作用及机制的研究进展,旨在探讨 PFKFB3 介导的糖酵解在肝纤维化中的作用,为以 PFKFB3 为靶点治疗肝纤维化的研究提供新思路。